Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 8 | 2024 | 68 | 1.000 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2026 | 463 | 0.770 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2026 | 372 | 0.610 |
Why?
|
| Vulvar Neoplasms | 2 | 2014 | 10 | 0.520 |
Why?
|
| Ovarian Neoplasms | 8 | 2025 | 165 | 0.480 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2005 | 151 | 0.430 |
Why?
|
| Cisplatin | 4 | 2024 | 147 | 0.390 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2011 | 260 | 0.270 |
Why?
|
| Uterine Neoplasms | 2 | 2026 | 36 | 0.260 |
Why?
|
| Paclitaxel | 2 | 2025 | 102 | 0.250 |
Why?
|
| Folate Receptor 1 | 1 | 2026 | 3 | 0.240 |
Why?
|
| Maytansine | 1 | 2026 | 6 | 0.240 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2026 | 17 | 0.240 |
Why?
|
| Immunoconjugates | 1 | 2026 | 95 | 0.230 |
Why?
|
| Carcinoma, Endometrioid | 4 | 2019 | 22 | 0.230 |
Why?
|
| Sirolimus | 2 | 2016 | 93 | 0.220 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2026 | 250 | 0.200 |
Why?
|
| Chemoradiotherapy | 1 | 2024 | 75 | 0.200 |
Why?
|
| Female | 27 | 2026 | 33927 | 0.190 |
Why?
|
| Hysterectomy | 2 | 2017 | 71 | 0.180 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2002 | 114 | 0.170 |
Why?
|
| Kidney Neoplasms | 1 | 2002 | 174 | 0.160 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2019 | 17 | 0.160 |
Why?
|
| Genital Neoplasms, Female | 1 | 1999 | 18 | 0.150 |
Why?
|
| Megestrol Acetate | 2 | 2016 | 3 | 0.150 |
Why?
|
| Tamoxifen | 2 | 2016 | 42 | 0.140 |
Why?
|
| Middle Aged | 13 | 2026 | 18208 | 0.140 |
Why?
|
| Receptor, Notch2 | 1 | 2017 | 8 | 0.130 |
Why?
|
| Humans | 27 | 2026 | 64954 | 0.130 |
Why?
|
| Cervix Uteri | 1 | 1997 | 58 | 0.130 |
Why?
|
| Aged | 11 | 2026 | 14924 | 0.120 |
Why?
|
| Gynecologic Surgical Procedures | 2 | 2014 | 49 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2025 | 217 | 0.120 |
Why?
|
| Adult | 13 | 2026 | 17313 | 0.120 |
Why?
|
| Preoperative Care | 2 | 2014 | 198 | 0.110 |
Why?
|
| Uterine Prolapse | 1 | 2014 | 17 | 0.110 |
Why?
|
| Colposcopy | 1 | 2014 | 20 | 0.100 |
Why?
|
| Papillomaviridae | 1 | 2014 | 59 | 0.100 |
Why?
|
| Endometrium | 1 | 2014 | 31 | 0.100 |
Why?
|
| Anaphylaxis | 1 | 1994 | 41 | 0.100 |
Why?
|
| Adnexal Diseases | 1 | 1993 | 8 | 0.100 |
Why?
|
| Mass Screening | 1 | 1999 | 696 | 0.100 |
Why?
|
| Laparoscopy | 1 | 2017 | 489 | 0.100 |
Why?
|
| Papillomavirus Infections | 1 | 2014 | 133 | 0.090 |
Why?
|
| Postoperative Care | 1 | 2013 | 125 | 0.090 |
Why?
|
| Surgical Procedures, Operative | 1 | 2013 | 141 | 0.090 |
Why?
|
| Herpes Zoster | 1 | 2011 | 22 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2013 | 291 | 0.090 |
Why?
|
| Lymphogranuloma Venereum | 1 | 1991 | 3 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2017 | 710 | 0.080 |
Why?
|
| Risk Factors | 3 | 2014 | 5408 | 0.080 |
Why?
|
| Epothilones | 1 | 2009 | 2 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2025 | 215 | 0.080 |
Why?
|
| Tubulin Modulators | 1 | 2009 | 6 | 0.080 |
Why?
|
| Peritoneal Neoplasms | 1 | 2009 | 30 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2002 | 1655 | 0.070 |
Why?
|
| Aged, 80 and over | 6 | 2017 | 5601 | 0.070 |
Why?
|
| Mutation | 1 | 2016 | 2657 | 0.070 |
Why?
|
| Aging | 1 | 2013 | 764 | 0.060 |
Why?
|
| Postoperative Complications | 3 | 2017 | 1314 | 0.060 |
Why?
|
| Skin Neoplasms | 1 | 2011 | 405 | 0.060 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 540 | 0.060 |
Why?
|
| Deoxycytidine | 1 | 2005 | 45 | 0.060 |
Why?
|
| Hemangiosarcoma | 1 | 2005 | 24 | 0.060 |
Why?
|
| Biopsy | 2 | 2014 | 454 | 0.050 |
Why?
|
| Brachytherapy | 1 | 2024 | 39 | 0.050 |
Why?
|
| Precancerous Conditions | 1 | 2004 | 74 | 0.050 |
Why?
|
| Neuralgia | 1 | 2003 | 21 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2024 | 3305 | 0.050 |
Why?
|
| Lymph Node Excision | 1 | 2002 | 45 | 0.050 |
Why?
|
| Diagnosis, Differential | 3 | 2011 | 988 | 0.050 |
Why?
|
| Nephrectomy | 1 | 2002 | 92 | 0.040 |
Why?
|
| Filgrastim | 1 | 2020 | 8 | 0.040 |
Why?
|
| Carboplatin | 1 | 2020 | 46 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2014 | 895 | 0.040 |
Why?
|
| Struma Ovarii | 1 | 1999 | 2 | 0.040 |
Why?
|
| Thyrotoxicosis | 1 | 1999 | 7 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 94 | 0.040 |
Why?
|
| Prognosis | 2 | 2002 | 1775 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2024 | 642 | 0.040 |
Why?
|
| Age Factors | 2 | 2017 | 1580 | 0.030 |
Why?
|
| Genetic Testing | 1 | 1999 | 141 | 0.030 |
Why?
|
| Ileus | 1 | 2017 | 6 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 739 | 0.030 |
Why?
|
| Uterine Cervical Diseases | 1 | 1997 | 4 | 0.030 |
Why?
|
| Laparotomy | 1 | 2017 | 54 | 0.030 |
Why?
|
| Retrospective Studies | 4 | 2017 | 6842 | 0.030 |
Why?
|
| Intraoperative Complications | 1 | 2017 | 88 | 0.030 |
Why?
|
| Papanicolaou Test | 1 | 1997 | 46 | 0.030 |
Why?
|
| Vaginal Smears | 1 | 1997 | 59 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 286 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 1999 | 317 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 112 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 9 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2017 | 161 | 0.030 |
Why?
|
| Postmenopause | 1 | 1997 | 238 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2016 | 88 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 178 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 210 | 0.030 |
Why?
|
| Pneumonia | 1 | 2017 | 291 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 583 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 1994 | 122 | 0.030 |
Why?
|
| Length of Stay | 1 | 2017 | 826 | 0.030 |
Why?
|
| Ovarian Diseases | 2 | 2004 | 19 | 0.030 |
Why?
|
| Fallopian Tubes | 1 | 1993 | 13 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 242 | 0.020 |
Why?
|
| Torsion Abnormality | 1 | 1993 | 12 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2020 | 5776 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 294 | 0.020 |
Why?
|
| Ovariectomy | 1 | 1993 | 103 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 221 | 0.020 |
Why?
|
| Quality of Life | 1 | 2020 | 1255 | 0.020 |
Why?
|
| Morbidity | 1 | 1993 | 110 | 0.020 |
Why?
|
| Ovary | 1 | 1993 | 105 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 316 | 0.020 |
Why?
|
| Patient Positioning | 1 | 2013 | 50 | 0.020 |
Why?
|
| Carcinoma | 1 | 1993 | 130 | 0.020 |
Why?
|
| Delirium | 1 | 2013 | 55 | 0.020 |
Why?
|
| Trophoblastic Neoplasms | 1 | 1992 | 2 | 0.020 |
Why?
|
| Forecasting | 1 | 1993 | 230 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2014 | 193 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2014 | 489 | 0.020 |
Why?
|
| Wound Healing | 1 | 2013 | 193 | 0.020 |
Why?
|
| Herpesvirus 3, Human | 1 | 2011 | 9 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 1997 | 2482 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 58 | 0.020 |
Why?
|
| Abdominal Wall | 1 | 2011 | 24 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 795 | 0.020 |
Why?
|
| Venous Thromboembolism | 1 | 2013 | 147 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2011 | 44 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2011 | 134 | 0.020 |
Why?
|
| Pelvis | 1 | 1991 | 62 | 0.020 |
Why?
|
| Cohort Studies | 1 | 1997 | 2614 | 0.020 |
Why?
|
| Pain Management | 1 | 2013 | 174 | 0.020 |
Why?
|
| Physical Examination | 1 | 1991 | 109 | 0.020 |
Why?
|
| Adolescent | 3 | 2004 | 6293 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 1991 | 231 | 0.020 |
Why?
|
| Bridged-Ring Compounds | 1 | 2009 | 8 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2009 | 23 | 0.020 |
Why?
|
| Taxoids | 1 | 2009 | 25 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2013 | 518 | 0.020 |
Why?
|
| Pregnancy | 2 | 1993 | 2372 | 0.020 |
Why?
|
| Pregnancy Complications | 1 | 1993 | 385 | 0.020 |
Why?
|
| Mesna | 1 | 2005 | 3 | 0.010 |
Why?
|
| Ifosfamide | 1 | 2005 | 8 | 0.010 |
Why?
|
| Dacarbazine | 1 | 2005 | 18 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2005 | 91 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2005 | 98 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 170 | 0.010 |
Why?
|
| Amitriptyline | 1 | 2003 | 7 | 0.010 |
Why?
|
| Fallopian Tube Diseases | 1 | 2003 | 6 | 0.010 |
Why?
|
| Child | 1 | 1993 | 4606 | 0.010 |
Why?
|
| Endometriosis | 1 | 2003 | 27 | 0.010 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2003 | 35 | 0.010 |
Why?
|
| Abscess | 1 | 2003 | 78 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2004 | 1138 | 0.010 |
Why?
|
| Thyroglobulin | 1 | 1999 | 9 | 0.010 |
Why?
|
| Triiodothyronine | 1 | 1999 | 30 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1999 | 128 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2004 | 1557 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2004 | 2094 | 0.010 |
Why?
|
| Cystadenoma | 1 | 1993 | 7 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1993 | 11 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 1993 | 42 | 0.010 |
Why?
|
| Dactinomycin | 1 | 1992 | 11 | 0.010 |
Why?
|
| World Health Organization | 1 | 1992 | 35 | 0.010 |
Why?
|
| Alleles | 1 | 1993 | 453 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1992 | 84 | 0.010 |
Why?
|
| Methotrexate | 1 | 1992 | 80 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1992 | 117 | 0.010 |
Why?
|
| Base Sequence | 1 | 1993 | 1329 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1993 | 1979 | 0.000 |
Why?
|
| United States | 1 | 1992 | 8083 | 0.000 |
Why?
|